[F:1][C:2]1[CH:3]=[C:4]([C:8]2[N:13]=[C:12](SC)[N:11]=[C:10]([N:16]3[CH2:21][CH2:20][O:19][CH2:18][C@@H:17]3[CH3:22])[CH:9]=2)[CH:5]=[N:6][CH:7]=1.ClC1N=C(N2CCOC[C@@H]2C)C=C(C2C=NC=C(F)C=2)N=1.[CH:44]1([NH:47][C:48]([NH:50][C:51]2[CH:56]=[CH:55][C:54](B3OC(C)(C)C(C)(C)O3)=[C:53]([F:66])[CH:52]=2)=[O:49])[CH2:46][CH2:45]1>>[CH:44]1([NH:47][C:48]([NH:50][C:51]2[CH:56]=[CH:55][C:54]([C:12]3[N:13]=[C:8]([C:4]4[CH:5]=[N:6][CH:7]=[C:2]([F:1])[CH:3]=4)[CH:9]=[C:10]([N:16]4[CH2:21][CH2:20][O:19][CH2:18][C@@H:17]4[CH3:22])[N:11]=3)=[C:53]([F:66])[CH:52]=2)=[O:49])[CH2:46][CH2:45]1Method as described for intermediate 5 using (S)-4-(2-chloro-6-(5-fluoropyridin-3-yl)pyrimidin-4-yl)-3-methylmorpholine (intermediate 7) and 1-cyclopropyl-3-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea (intermediate 11). Material was purified by prep HPLC twice (low pH) followed by purification using a TsOH cartridge (100 mg) to afford a yellow solid, (4.5 mg, 15%)
Loading…